Overview

Efficacy and Safety of Rabbit Antithymocyte Globulin 3mg/kg in Kidney Transplant Patients Under Steroid-free and CNI Minimization Maintenance Immunosuppressive Regimen

Status:
Unknown status

Trial end date:
2020-01-01

Target enrollment:

Participant gender:

Summary

Single-center, prospective, randomized, open-label clinical trial to evaluate the 1-year efficacy and safety of rATG 3mg/kg compared to 6mg/kg in low to moderate immunological risk patients receiving low exposure tacrolimus plus everolimus (EVL) in a steroid-free protocol.

Phase:

Phase 4

Details

Lead Sponsor:

Hospital Geral de Fortaleza

Treatments:

Antilymphocyte Serum
Immunosuppressive Agents
Thymoglobulin